Novel Serotonergic Psychedelic Agents as 5-HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders
ACS Medicinal Chemistry Letters August 25, 2025 DOI: 10.1021/acsmedchemlett.5c00484 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Patent Peer reviewed |
|---|---|
| Topics | Serotonin |
| Keywords | Psychosis Mental illness Psychotherapist Receptor Mental health |
| Key points | Argues that novel 5-HT2A agonist compounds can be used in pharmaceutical compositions to treat psychosis, mental illness, and CNS disorders. |
Abstract
High Resolution Image Download MS PowerPoint Slide Provided herein are novel serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
Citations in the library
Cites 5
- 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacological Reviews April 23, 2025
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications. Brain Sciences January 25, 2025
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders. ACS Medicinal Chemistry Letters February 11, 2025